Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC)-Reference-Cited by-同舟云学术

Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC)

Published:2005-06 Issue:16_suppl Volume:23 Page:764-764
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Penault-Llorca F.¹,Vincent-Salomon A.¹,Mathieu M. C.¹,Trillet-Lenoir V.¹,Khayat D.¹,Marty M.¹

Affiliation:

1. Ctr Jean Perrin, Clermont Ferrand, France; Inst Curie, Paris, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier Lyon Sud, Lyon, France; Hosp de la Pitie Salpetriere, Paris, France

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.764

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab (Herceptin®) and Ado-Trastuzumab Emtansine (Kadcyla®): Treatments for HER2-Positive Breast Cancer;Handbook of Therapeutic Antibodies;2014-08-12

2. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients;Expert Review of Anticancer Therapy;2012-11

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;The Lancet;2010-08

4. Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel inHER2-Positive Metastatic Breast Cancer;Journal of Clinical Oncology;2010-02-20

5. Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study;Journal of Clinical Oncology;2009-11-20